SalaryGuide
AboutPricingFor Employers

Marketing jobs

2 marketing jobs

Travere Therapeutics logo
3 days ago

Associate Director, FILSPARI HCP Marketing

Travere Therapeutics

San Diego, CA (Unknown)Full time$150K/yr – $195K/yr
Travere Therapeutics logo
3 days ago

Associate Director, FILSPARI HCP Marketing

Travere Therapeutics

San Diego, CA (Hybrid)Full time$150K/yr – $195K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

2 jobs
Travere Therapeutics logo

Associate Director, FILSPARI HCP Marketing

Travere Therapeutics

San Diego, CA (Unknown)

$150K/yr - $195K/yrIn-houseFull-timeSenior level8+ years exp.
3 days ago
Travere Therapeutics logo

Associate Director, FILSPARI HCP Marketing

Travere Therapeutics

San Diego, CA (Hybrid)

$150K/yr - $195K/yrIn-houseFull-timeMid level8+ years exp.
3 days ago
Travere Therapeutics logo
Travere Therapeutics

Associate Director, FILSPARI HCP Marketing

San Diego, CA (Unknown)

$150K/yr – $195K/yrSenior Level8+ years expFull time

Posted 3 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the end-to-end HCP and P2P marketing for FILSPARI, translating strategy into briefs, tactics and budgets while stewarding the Promotional Review Committee process and cross-functional collaboration.

  • Plan and execute HCP marketing tactics and content ownership through approvals
  • Coordinate with Sales, Digital Marketing, and agencies on resources, timelines, and spend

Job Description

Responsibilities

  • Support the Director, HCP Marketing and the Director, Thought Leader Liaisons in the development and evolution of integrated HCP and P2P strategy, priorities, messaging, and annual brand and tactical plans; translate approved direction into objectives, briefs, deliverables, resource requirements, timelines, and measures of success for assigned tactics.
  • Independently lead the planning and execution of HCP marketing tactics for FILSPARI; serve as the business and content owner for assigned materials through the Promotional Review Committee process; prepare business rationale, lead agency revisions, resolve comments with Committee partners, and secure final approval; partner with Marketing Services, Commercial Operations and agency partners on review scheduling, documentation, Veeva workflow, production, distribution, and content-library management.
  • Support the execution of P2P content and materials within strategies and priorities established by HCP and Thought Leader Liaison leadership for speaker programming and advisory boards; incorporate KOL insight, advocacy guidance, field feedback, and market intelligence into execution plans.
  • Partner with Sales Leadership, Sales Training and the field Marketing Advisory Board on the development and deployment of promotional resources for the national Clinical Account Management team; support the Director, HCP Marketing with HCP Marketing content for national sales meetings, plan-of-action meetings, and field training initiatives.
  • Partner with Digital Marketing on optimization of HCP websites and NPP content and assets; within the approved HCP content strategy, lead creative briefs, asset development, and promotional review, while Digital Marketing owns channel architecture, technical and measurement requirements, deployment or activation, and ongoing optimization.
  • Manage assigned tactic budgets, forecasts, scopes of work, and invoice review within approved HCP Marketing plan; partner with Contracts and Procurement on purchase orders and vendor workflows, recommend resource trade-offs and adjustments to leadership, and ensure investments deliver against business objectives.

Requirements

  • Bachelor's Degree in Business, Marketing, a relevant Life Sciences discipline, or a related field. Master’s Degree preferred. An equivalent combination of education and applicable job experience may be considered.
  • Minimum 8+ years of progressive marketing experience in the biotechnology or pharmaceutical industry, or related agency experience.
  • Prior leadership experience driving operational implementation and excellence, with accountability for external resources and budgets; demonstrated HCP marketing and regulated content-development experience for in-market and/or launch or indication-expansion products, including personal promotion, agency leadership, complex project management, and promotional review. Rare disease, nephrology, HCP Marketing, P2P Marketing, or speaker programming and operations, experience is preferred.
  • The ideal candidate will embody Travere's core values: Courage, Community Spirit, Patient Focus, and Teamwork.
  • Broad HCP marketing expertise and ability to solve complex, cross-functional challenges using sound judgment and an understanding of functional strategy.
  • Ability to independently develop recommendations and project plans, make defined decisions within established strategy, and manage risks affecting department-wide outcomes.
  • Demonstrated ability to influence stakeholders in complex situations while preserving relationships and achieving cross-functional alignment.
  • Strong business and scientific acumen, with the ability to translate customer and market insights into clear communication objectives, content strategies, and actionable tactical plans.
  • Successful record of managing agencies, external resources, complex project plans, timelines, budgets, scopes, and critical paths across multiple concurrent workstreams.
  • Experience achieving commercial objectives in a highly regulated environment, with a strong understanding of promotional review, compliant HCP communications, and cross-functional governance.
Travere Therapeutics logo

Travere Therapeutics

4.3 Glassdoor

Our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife Community Guidelines: https://travere.com/community-guidelines/

Founded in 2020
San Diego, California, USA
489 employees (23 in marketing)
www.travere.com
83% recommend to a friend
93% CEO approval

Traffic Signals

Monthly Visitors
12.7K
Traffic Source Mix
Search
44.7%
Direct
47.6%
Referral
5.5%
Social
0.5%
Paid
1.6%

Headcount Trend

Current headcount: ~489

Marketing Team

Marketing Team Size
23 (5% of company)
Median Career Experience
15 years
Median Tenure
1.7 years
Marketing Roles Posted (Last 30 Days)
1

People

Founders / CEO

Eric Dube
Eric Dube
CEO
At the company for 7 years 8 months

HR / Recruitment

Becky Mallek
Becky Mallek
Talent Acquisition Manager
At the company for 1 year 11 months
Dawn Taylor, SHRM-CP
Dawn Taylor, SHRM-CP
Talent Acquisition Manager
At the company for 1 year 7 months

Marketing Leadership

Carrie De Smet
Carrie De Smet
Associate Director, Patient Marketing
At the company for 1 year 3 months
Tracie Sadowski, MBA
Tracie Sadowski, MBA
Associate Director, HCP Marketing - Digital and Omnichannel Strategy
At the company for 1 year 4 months
Tracie Harris Rice
Tracie Harris Rice
Associate Director Marketing
At the company for 2 years 2 months
Kyle Poe
Kyle Poe
Senior Director, Healthcare Provider Marketing
At the company for 4 years 2 months

Funding

Total Funding
$1.1B
Last Raise
$125M
Post IPO Equity, 1 years ago

Funding History

  • Nov 2024
    Post IPO Equity • $125M
  • Feb 2023
    Post IPO Equity • $200M
  • Mar 2022
    Post IPO Debt • $275M

Recent News

Why IBD 50's No. 2 Stock, Travere Therapeutics, Has Doubled In 2025
Nov 26, 2025 • Investor's Business Daily
Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA (TVTX)
Nov 26, 2025 • Seeking Alpha
Will Positive Phase 3 FILSPARI Data in FSGS Redefine Travere Therapeutics' (TVTX) Position in Rare Kidney Disease?
Nov 19, 2025 • simplywall.st
A Look at Travere Therapeutics (TVTX) Valuation Following Positive FILSPARI Phase 3 Kidney Data Release
Nov 18, 2025 • simplywall.st
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally
Nov 18, 2025 • The Motley Fool
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally
Nov 18, 2025 • AOL.com
Travere Therapeutics : Investor Fact Sheet
Nov 16, 2025 • MarketScreener
Travere Therapeutics at TD Cowen Summit: Strategic Insights on Kidney Treatments
Nov 13, 2025 • Investing.com
Why Travere Therapeutics (TVTX) Is Up 5.8% After Promising Phase 3 FILSPARI Data in FSGS Patients
Nov 12, 2025 • simplywall.st
Travere Therapeutics at Guggenheim Conference: Rare Disease Focus
Nov 11, 2025 • Investing.com
Optimistic Buy Rating for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Positioning
Nov 9, 2025 • TipRanks
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
Nov 6, 2025 • Business Wire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Surges 29% Yet Its Low P/S Is No Reason For Excitement
Nov 6, 2025 • simplywall.st
Travere Therapeutics Hits New 52-Week High of $35.34, Marking Major Growth
Nov 5, 2025 • Markets Mojo
Travere Therapeutics to Participate at Upcoming Investor Conferences
Nov 4, 2025 • The Joplin Globe
Travere Therapeutics to Participate at Upcoming Investor Conferences
Nov 4, 2025 • Business Wire
Insider Sell Alert: Peter Heerma Sells Shares of Travere Therape
Nov 4, 2025 • GuruFocus
Travere Therapeutics Stock (TVTX) Opinions on Q3 Earnings Surge
Nov 2, 2025 • Quiver Quantitative
Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings
Nov 2, 2025 • Yahoo Finance
A Look at Travere Therapeutics's Valuation Following Strong Q3 Profit and FILSPARI Momentum
Nov 1, 2025 • Yahoo Finance
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook
Nov 1, 2025 • Insider Monkey
Travere Therapeutics Delivers Growth As FILSPARI Drives Profits
Oct 31, 2025 • Finimize
Travere Therapeutics’ Strong Quarter and Future Prospects
Oct 31, 2025 • TipRanks
Travere Therapeutics : Corporate Overview – October 2025
Oct 31, 2025 • MarketScreener
Travere Therapeutics (TVTX) Sees Increased Price Target and Posi
Oct 31, 2025 • GuruFocus
Travere Therapeutics stock hits 52-week high at 33.66 USD
Oct 31, 2025 • Investing.com
Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates
Oct 30, 2025 • Yahoo Finance
Travere Therapeutics Reports Strong Q3 2025 Growth
Oct 30, 2025 • TipRanks
Travere Therapeutics Reports Third Quarter 2025 Financial Results
Oct 30, 2025 • Business Wire
Travere Therapeutics (TVTX) Exceeds Q3 Revenue Expectations, Eyes Future Growth
Oct 30, 2025 • GuruFocus
Earnings call transcript: Travere Therapeutics Q3 2025 beats revenue forecasts
Oct 30, 2025 • Investing.com
Travere Therapeutics Q3 2025 Earnings Preview
Oct 29, 2025 • MSN
Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Report Preview: What To Expect
Oct 29, 2025 • GuruFocus
Travere Therapeutics Data Breach Lawsuit Investigation
Oct 27, 2025 • Claim Depot
Travere Therapeutics Data Breach Exposes Social Security Numbers
Oct 27, 2025 • Claim Depot
Can Travere Therapeutics Inc. stock maintain growth trajectory - July 2025 Volume & Daily Stock Trend Watchlist
Oct 27, 2025 • newser.com
Can Travere Therapeutics Inc. stock deliver strong Q4 earnings - Market Risk Analysis & Trade Opportunity Analysis Reports
Oct 27, 2025 • newser.com
Will Travere Therapeutics Inc. stock gain from strong economy - 2025 Technical Patterns & Real-Time Buy Signal Notifications
Oct 27, 2025 • newser.com
How moving averages guide Travere Therapeutics Inc. trading - Weekly Investment Recap & Intraday High Probability Setup Alerts
Oct 27, 2025 • newser.com
When is the best time to exit Travere Therapeutics Inc. - Oil Prices & AI Optimized Trading Strategy Guides
Oct 27, 2025 • newser.com
How moving averages guide Travere Therapeutics Inc. trading - July 2025 Movers & High Yield Equity Trading Tips
Oct 27, 2025 • newser.com
Pattern recognition hints at Travere Therapeutics Inc. upside - July 2025 Volume & Growth Focused Stock Reports
Oct 27, 2025 • newser.com
Pattern recognition hints at Travere Therapeutics Inc. upside - Analyst Upgrade & Growth Oriented Trading Recommendations
Oct 26, 2025 • newser.com
Backtesting results for Travere Therapeutics Inc. trading strategies - 2025 Market Overview & Daily Risk Controlled Trade Plans
Oct 26, 2025 • newser.com
Why Travere Therapeutics Inc. stock could outperform in 2025 - New Guidance & High Conviction Investment Ideas
Oct 26, 2025 • newser.com
Can Travere Therapeutics Inc. stock maintain growth trajectory - 2025 Trade Ideas & Smart Swing Trading Techniques
Oct 26, 2025 • newser.com
Can Travere Therapeutics Inc. stock deliver strong Q4 earnings - July 2025 Breakouts & Reliable Price Breakout Alerts
Oct 26, 2025 • newser.com
Assessing Travere Therapeutics After Regulatory Wins and a 48% Rally in 2025
Oct 24, 2025 • simplywall.st
Travere Therapeutics to Report Third Quarter 2025 Financial Results
Oct 23, 2025 • The Globe and Mail
Biotech Leader Travere Therapeutics Eyes Buy Point After More Than Doubling
Oct 23, 2025 • Investor's Business Daily
Should You Rethink Travere After Shares Surge 48% and Pipeline Progress Headlines?
Oct 23, 2025 • Yahoo Finance
What moving averages say about Travere Therapeutics Inc. - July 2025 Spike Watch & Daily Chart Pattern Signal Reports
Oct 22, 2025 • newser.com
FILSPARI’s New Clinical Data Might Change the Case for Investing in Travere Therapeutics (TVTX)
Oct 20, 2025 • Sahm
What is the fair value of Travere Therapeutics Inc. stock now - 2025 Breakouts & Breakdowns & High Conviction Buy Zone Picks
Oct 18, 2025 • Trung tâm Dự báo KTTV quốc gia
A Look at Travere Therapeutics's Valuation Following Positive FILSPARI Results Presented at ASN Kidney Week 2025
Oct 18, 2025 • simplywall.st
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
Oct 17, 2025 • Business Wire
What Makes Travere (TVTX) a New Strong Buy Stock
Oct 15, 2025 • Yahoo Finance
Can Travere Therapeutics Sustain Its 48.9% Rally Amid Pipeline Progress in 2025?
Oct 8, 2025 • Yahoo Finance
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Sep 26, 2025 • Business Wire
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Sep 26, 2025 • PR Newswire
H.C. Wainwright reiterates Buy rating on Travere Therapeutics stock
Sep 22, 2025 • Investing.com
Travere Therapeutics Receives Composite Rating Upgrade
Sep 22, 2025 • Investor's Business Daily
Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS (NASDAQ:TVTX)
Sep 12, 2025 • Seeking Alpha
H.C. Wainwright reiterates buy rating on Travere Therapeutics stock
Sep 11, 2025 • Investing.com
Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside
Sep 11, 2025 • Yahoo Finance
Travere Shares Are Trading Higher Wednesday: What's Going On? - Travere Therapeutics (NASDAQ:TVTX)
Sep 10, 2025 • Benzinga
AdCom cancellation ‘clear positive’ for Travere Therapeutics, says Jefferies
Sep 10, 2025 • TipRanks
Travere says no FDA AdCom for Filspari review (TVTX:NASDAQ)
Sep 10, 2025 • Seeking Alpha
H.C. Wainwright reiterates Buy rating on Travere Therapeutics stock
Sep 10, 2025 • Investing.com
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application
Sep 10, 2025 • Stocktwits
Improved Revenues Required Before Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock's 26% Jump Looks Justified
Sep 6, 2025 • simplywall.st
Travere Therapeutics Shows Rising Price Performance With Jump To 92 RS Rating
Sep 5, 2025 • Investor's Business Daily
Travere Therapeutics CFO Sells Shares to Cover Tax Obligations
Sep 5, 2025 • TradingView
Travere Therapeutics at Cantor Conference: Strategic Insights on FILSPARI
Sep 4, 2025 • Investing.com
Travere Therapeutics at Wells Fargo Conference: Strategic Growth and Challenges
Sep 3, 2025 • Investing.com
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
Sep 3, 2025 • Yahoo Finance
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
Sep 3, 2025 • sdbn.org
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
Sep 3, 2025 • BioSpace
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
Sep 3, 2025 • Business Wire
Travere Therapeutics at Citi’s Biopharma Conference: Strategic Insights
Sep 2, 2025 • Investing.com
Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch
Aug 28, 2025 • Investor's Business Daily
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
Aug 28, 2025 • BioSpace
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
Aug 28, 2025 • Benzinga.com
Victoria's Secret, Copper miners, Dell
Aug 28, 2025 • Reuters
FDA Approves REMS Label Update for Sparsentan (Filspari) in IgA Nephropathy
Aug 27, 2025 • HCPLive
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI
Aug 27, 2025 • Business Wire
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
Aug 27, 2025 • MarketScreener
Travere Therapeutics Sees Relative Strength Rating Rise To 73
Aug 14, 2025 • Investor's Business Daily
Travere Therapeutics at Canaccord Genuity: Strategic Insights from Growth Conference
Aug 13, 2025 • Investing.com
Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore (NASDAQ:TVTX)
Aug 12, 2025 • Seeking Alpha
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 11, 2025 • Business Wire
Travere Therapeutics price target raised to $32 from $30 at Wedbush
Aug 8, 2025 • Yahoo Finance
Earnings call transcript: Travere Therapeutics Q2 2025 beats revenue forecasts
Aug 7, 2025 • Investing.com
Transcript : Travere Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025
Aug 7, 2025 • MarketScreener
Travere Therapeutics Reports Second Quarter 2025 Financial Results
Aug 7, 2025 • BioSpace
Travere Therapeutics, Inc. SEC 10-Q Report
Aug 6, 2025 • TradingView
Travere Therapeutics earnings beat by $0.16, revenue topped estimates
Aug 6, 2025 • Investing.com
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
Aug 6, 2025 • Yahoo Finance
Travere Therapeutics Reports Strong Q2 2025 Growth
Aug 6, 2025 • TipRanks
Travere Therapeutics to Participate at Upcoming Investor Conferences - August 5, 2025
Aug 6, 2025 • BioSpace